Italia markets open in 1 hour 6 minutes

Basilea Pharmaceutica AG (0QNA.L)

LSE - LSE Prezzo differito. Valuta in CHF.
Aggiungi a watchlist
32,57+1,80 (+5,84%)
Alla chiusura: 06:07PM BST
Schermo intero
Chiusura precedente30,77
Aperto32,60
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno32,55 - 32,65
Intervallo di 52 settimane32,55 - 32,65
Volume1.016
Media VolumeN/D
Capitalizzazione351,387M
Beta (5 anni mensile)1,00
Rapporto PE (ttm)N/D
EPS (ttm)-0,58
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Basilea announces licensing of a novel first-in-class antifungal program from Fox Chase Chemical Diversity Center

    Basel, Switzerland, April 27, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with bacterial and fungal infections and cancer, announced today that it has entered into a licensing agreement with the U.S.-based company, Fox Chase Chemical Diversity Center, Inc. (FCCDC), for a preclinical program on novel first-in-class broad spectrum antifungals with activity against difficult-to-treat mold infections. Dr. Lauren

  • GlobeNewswire

    Basilea shareholders approve all proposals of the board of directors at the annual general meeting

    Press Release Basel, Switzerland, April 13, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that shareholders approved all proposals of the board of directors at today’s annual general meeting (AGM) for the financial year 2021. In accordance with the COVID-19 Ordinance 3 issued by the Swiss Federal Council, the board of directors of Basilea Pharmaceutica Ltd. had decided to hold the AGM 2022 without the physical presence of shareholders. Accordingly, shareholders exercised their votin

  • GlobeNewswire

    Basilea reports preclinical data on oncology drug candidates BAL0891, derazantinib and lisavanbulin at AACR Annual Meeting

    Basel, Switzerland, April 13, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, reported today that promising preclinical data on the anti-cancer activity of its three oncology drug candidates, BAL0891, derazantinib and lisavanbulin, have been presented at the Annual Meeting of the American Association for Cancer Research (AACR) that took place April 8-13, 2022, in New Orleans,